Company: PHAT
Filing Date: 2025-03-06
Form Type: 10-K
Source: 0000950170-25-034183
Chunk: 254

Company: Phathom Pharmaceuticals, Inc.
Filing Date: 2025-03-06
Form: 10-K
Item: Item 1B
Chunk 254
---
 Proxy Statement and is incorporated herein by reference.

The information required by Item 201(d) of Regulation S-K will be set forth in the section headed “Executive Compensation and Other Information” in our Definitive Proxy Statement and is incorporated herein by reference. 

Item 13.	Certain Relationships and Related Transactions, and Director Independence 

The information required by this item will be set forth in the section headed “Certain Relationships and Related Person Transactions,” “Director Independence” and “Board Committees and Independence” in our Definitive Proxy Statement and is incorporated herein by reference.  

Item 14.	Principal Accountant Fees and Services 

The information required by this item will be set forth in the section headed “Independent Registered Public Accounting Firm's Fees” in our Definitive Proxy Statement and is incorporated herein by reference.

117

PART IV 

Item 15. Exhibits and Financial Statement Schedules 

1.All financial statements.

The financial statements of Phathom Pharmaceuticals, Inc., together with the report thereon of Ernst & Young LLP, an independent registered public accounting firm, are included in this annual report on Form 10-K beginning on page F-1. 

2.Financial statement schedules.

All schedules have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes thereto. 

3.Exhibits

A list of exhibits is set forth on the Exhibit Index immediately preceding the signature page of this annual report on Form 10-K and is incorporated herein by reference. 

Item 16. Form 10-K Summary

None.

118

Phathom Pharmaceuticals, Inc. 

Index to Financial Statements 

    Page

    Report of Independent Registered Public Accounting Firm (PCAOB ID: 42)
    F-2

    Balance Sheets
    F-4

    Statements of Operations and Comprehensive Loss
    F-5

    Statements of Stockholders’ Deficit
    F-6

    Statements of Cash Flows
    F-7

    Notes to Financial Statements
    F-8

F-1

Report of Independent Registered Public Accounting Firm 

To the Stockholders and the Board of Directors of Phathom Pharmaceuticals, Inc.

Opinion on the Financial Statements

We have audited the accompanying balance sheets of Phathom Pharmaceuticals, Inc. (the Company) as of December 31, 2024 and 2023, the related statements of operations and comprehensive loss, stockholders' deficit and cash flows for each of the two years in the period